<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disease outcome and functional capacity in rheumatoid arthritis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disease outcome and functional capacity in rheumatoid arthritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Disease outcome and functional capacity in rheumatoid arthritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon T Giles, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) has a variable disease course that can potentially result in physical disability, work-loss, increased risk of certain comorbid illnesses, and early death. However, effective, timely treatment is likely to modify disease activity and disease progression and can improve long-term outcomes.</p><p>Functional capacity, comorbidities, and mortality in RA are reviewed here. Specific instruments for assessment of disease activity and function, clinical manifestations of RA, and strategies for effective disease management are described separately. (See  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function"</a> and  <a class="medical medical_review" href="/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p class="headingAnchor" id="H2504848646"><span class="h1">DISEASE COURSE AND OUTCOME</span><span class="headingEndMark"> — </span>The course of rheumatoid arthritis (RA) is variable [<a href="#rid1">1</a>]; both short- and long-term disease outcomes, which can benefit from early and aggressive treatment, depend upon multiple factors [<a href="#rid2">2</a>]. Most patients have progressive disease, which can take either a slow or a rapid course, and approximately 15 to 20 percent of patients have intermittent disease with periods of exacerbation and a relatively good prognosis. (See  <a class="medical medical_review" href="/d/html/7502.html" rel="external">"Clinical manifestations of rheumatoid arthritis"</a>.) </p><p>The outcome of RA depends upon several factors, including the degree of joint damage, the physical functional status of the patient, psychological health, and the presence of comorbid illnesses (see <a class="local">'Functional outcomes'</a> below). These comorbidities include cardiovascular, pulmonary and infectious disease; certain cancers; and other disorders. A reduced life expectancy can be seen in some patients with severe RA, due to illnesses that may be the result of RA itself or the drugs used in its treatment (<a class="graphic graphic_table graphicRef82537" href="/d/graphic/82537.html" rel="external">table 1</a>). (See <a class="local">'Impact of comorbidities'</a> below and <a class="local">'Mortality'</a> below.)</p><p>A treatment approach that focuses on aggressive management early in the disease course, with an emphasis on attaining and maintaining low articular disease activity or remission, is associated with improved life expectancy for people with RA and a reduction in the prevalence of some RA-associated comorbidities. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Management strategies'</a> and <a class="local">'Impact of comorbidities'</a> below and <a class="local">'Impact of therapy'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">FUNCTIONAL CAPACITY</span></p><p class="headingAnchor" id="H2684770110"><span class="h2">Factors affecting physical function and disability</span><span class="headingEndMark"> — </span>Loss of functional capacity in rheumatoid arthritis (RA) is a result of the summation of loss of function in individual joints, but is also affected by muscle function and metabolic factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Joint function</strong> – Individual joint function depends upon numerous factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severity of disease activity (ie, burden of synovitis)</p><p class="bulletIndent2"><span class="glyph">•</span>Structural integrity of a joint</p><p class="bulletIndent2"><span class="glyph">•</span>Muscle strength and tone</p><p class="bulletIndent2"><span class="glyph">•</span>General fitness of the patient</p><p class="bulletIndent2"><span class="glyph">•</span>Psychosocial factors</p><p></p><p class="bulletIndent1">The articular component of functional disability is predominantly due to inflammatory synovitis during the early stage of the disease, loss of structural integrity of joints at a late stage, and, depending upon the level of disease activity, a combination of both for the rest of the course of disease [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">While recognizing the limitations of self-reports of physical function, there is evidence that the common-sense notion that the combination of inflammation and joint damage leads to functional limitation is correct. This was illustrated by the results of a Finnish population-based survey of 1095 patients with an established diagnosis of RA and 1530 age- and sex-matched controls [<a href="#rid4">4</a>]. A score on the Health Assessment Questionnaire (HAQ) of more than 1 suggests that a person is having difficulty with most activities of daily living. Patients were nearly eight times more likely to report moderate disability (HAQ score ≥1) than controls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body composition</strong> – The effect of RA inflammation and joint damage on physical function appears to extend beyond the direct effects of synovitis and erosive joint damage; RA patients tend to have lower muscle mass, lower muscle density, and more body fat compared with otherwise similar individuals without RA [<a href="#rid5">5-7</a>].</p><p></p><p class="bulletIndent1">Individuals with RA who had lower muscle mass, particularly lower density muscle, and higher fat mass reported worse physical function and demonstrated lower scores on physical performance testing compared with those with better muscle and fat composition [<a href="#rid7">7,8</a>]. Patients with RA who were obese also had worse disease and a poorer response to anti-tumor necrosis factor (TNF) therapy [<a href="#rid9">9</a>]. The effects of body composition on performance were as great as or greater than the contributions from synovitis, joint deformity, and psychosocial factors. Notably, physical function among those with higher levels of joint swelling and/or deformity was better for those with more optimal body composition compared with those with similar levels of articular disease activity and damage but with suboptimal fat and muscle composition [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial factors</strong> – Psychosocial factors are an important component of the non-articular issues that may adversely affect functional status. These factors that affect psychosocial health and function, including learned helplessness, reduced sense of self-efficacy, and depression, may account for an estimated 10 to 20 percent of disability measured by both questionnaire-based instruments and by tests of walking speed [<a href="#rid10">10-12</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Assessment of functional status</span><span class="headingEndMark"> — </span>A number of instruments (eg, the Stanford HAQ and its modifications) have been developed for quantitative structured assessment of patients' functional status, an outcome of direct importance to patients with RA. These measures are useful for the assessment of patient outcomes in clinical practice, in response to specific therapies in clinical trials, and for the study of the natural history and course of disease over time. (See  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Assessment of physical function'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Instruments for routine clinical use</strong> – Three patient-reported functional status assessment measures for RA have been endorsed for clinical use by the American College of Rheumatology based upon consideration of both psychometric/clinimetric properties and ease of use in the clinical setting [<a href="#rid13">13</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The HAQ-II and the Multidimensional HAQ (MD-HAQ), which are both modifications of the more detailed original HAQ [<a href="#rid14">14-20</a>]. The MD-HAQ is used as a component of the Routine Assessment of Patient Index Data 3 (RAPID3) disease activity assessment instrument that is increasingly utilized in routine clinical practice [<a href="#rid21">21</a>]. The forms for the HAQ, the HAQ-II, and the MD-HAQ can be obtained from online sources (eg, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Frheuminfo.com%2Fphysician-tools%2Fhealth-assessment-questionnaires-haq-haq-ii-mdhaq%2F&amp;token=Ckvi%2FGNbs8K2BC6VqDZ8vv6NzXAp9kW7kKROT6gOTi6QNpIX3yWKM%2B%2BJAVRDkbFhGCp9ngU0mBUxMLHhzYYTWJaggaLIITrHbmI47mCQdzw%3D&amp;TOPIC_ID=7505" target="_blank">rheuminfo.com/physician-tools/health-assessment-questionnaires-haq-haq-ii-mdhaq/</a>). (See  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Health Assessment Questionnaire (HAQ)'</a> and  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Routine Assessment of Patient Index Data 3 (RAPID3)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 10-item Patient-Reported Outcomes Measurement Information System (PROMIS) physical function questionnaire, which was not developed based on the legacy HAQ instrument. It can be obtained from the National Institutes of Health (NIH) website (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthmeasures.net%2Fexplore-measurement-systems%2Fpromis&amp;token=hDyBhXQdVk422gHHSs8VgcMirSi%2FAAkIbVymhHxkfKZby%2B9ZTVxrYZNmduDeJZLBowWJB30hEo6Ypv2cuqhQb2QJx%2FnYGS0ly6g1GezFdKQ%3D&amp;TOPIC_ID=7505" target="_blank">https://www.healthmeasures.net/explore-measurement-systems/promis</a>). (See  <a class="medical medical_review" href="/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function", section on 'Physical Function 10-item Short Form (PROMIS PF10a)'</a>.)</p><p></p><p class="bulletIndent1">Patient-reported functional disability measures were developed as a result of a series of efforts to classify and grade functional capacity based upon the patient's ability to undertake daily activities in the home, at work, or during leisure time. The functional status questionnaires are limited, however, by their emphasis on the physical impact of RA, rather than the psychological health of the patient or the familial, social, and financial consequences of the disease. Indeed, further studies have suggested that psychosocial factors may contribute between 10 to 20 percent towards disability (see <a class="local">'Factors affecting physical function and disability'</a> above). All of these important issues contribute to the patient's quality of life [<a href="#rid22">22</a>]. Thus, a holistic approach to managing patients with RA requires careful attention to many potential consequences of this chronic disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other measures</strong> – Another of the initial well-studied and validated functional disability indices based on self-report questionnaires and which was used for this purpose included the Arthritis Impact Measurement Scale Health Status Questionnaire (AIMS) [<a href="#rid23">23</a>]. However, the complexity of this questionnaire, like the HAQ, and the time required for completion led to its modification and simplification for use in routine management.</p><p></p><p class="headingAnchor" id="H1214318333"><span class="h1">FUNCTIONAL OUTCOMES</span></p><p class="headingAnchor" id="H5"><span class="h2">Long-term outcomes</span><span class="headingEndMark"> — </span>Long-term functional outcomes for patients with rheumatoid arthritis (RA) vary widely, but most studies have shown improved outcomes with early effective intervention with disease-modifying antirheumatic drugs (DMARDs) and use of approaches favoring tight control of disease activity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Range of long-term outcomes</strong> – The long-term functional outlook is variable for patients who present early in the course of their illness and are treated. As an example, in a 2002 report of a study that prospectively followed 168 Swedish patients for 10 years or more, 94 percent continued to be independent in their daily activities [<a href="#rid24">24</a>]. The proportions of those with "almost no disability," mild, moderate, and serious disability based on the HAQ were 20, 28, 48, and 10 percent, respectively, at the end of observation. Almost 20 percent of patients had quiescent disease when last examined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of therapeutic advances</strong> – Use of effective DMARDs and DMARD treatment strategies has been increasing, and this may be having a favorable effect on the severity of disability of patients with RA, in particular, the more widespread adoption of the treat-to-target approach with low disease activity or remission as the target. Among 472 Dutch RA patients enrolled in an observational cohort using a treat-to-target protocol aimed at remission induction, those who achieved remission within the first six months of disease had Health Assessment Questionnaire (HAQ) scores at one year that were approximately half of those who did not achieve early remission [<a href="#rid25">25</a>]. Differences were maintained at three years but narrowed slightly by five years of follow-up. This narrowing in the difference in HAQ was due to increases in HAQ in the early-remission group between three and five years of follow-up, although it should be noted that the increases, on average, were less than the established minimal clinically important change in HAQ of 0.22 to 0.25 units.</p><p></p><p class="bulletIndent1">Some studies indicate that the trend towards more aggressive and early RA treatment in the early 21<sup>st</sup> century may not have reduced the risk of long-term disability as expected. A study of 8678 patients from the Swiss national RA cohort found that disability scores (measured by the HAQ) worsened by 1.8 percent per year [<a href="#rid26">26</a>]. A second study of 2500 patients from 3 prospective cohorts found that patients with equivalent levels of inflammation may still have different long-term outcomes (measured by the HAQ) [<a href="#rid27">27</a>]. In this study, higher levels of fatigue, depression, and pain were all associated with higher levels of long-term disability.</p><p></p><p class="bulletIndent1">Those with autoantibody-positive RA exhibit the largest temporal improvement in HAQ for the most recent treatment era compared with past eras [<a href="#rid28">28</a>]. Autoantibody-negative RA patients showed little temporal change in how their HAQ responded to treatment across eras.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term benefits of early intervention</strong> – The beneficial effects of antirheumatic drug treatment on function may be determined, at least in part, by the amount of joint damage that is present at the time such therapy is initiated. This was illustrated in retrospective study data from two trials that had randomly assigned patients with moderate to severe RA, who had not responded fully to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), to receive either <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> or placebo [<a href="#rid29">29,30</a>]; improvement in function as measured by HAQ was inversely correlated with the amount of baseline radiographic damage [<a href="#rid31">31</a>]. These findings suggest that interventions that are effective in preventing joint damage may be most effective in improving function when introduced as early as possible. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Management strategies'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Impact on employment</span><span class="headingEndMark"> — </span>RA may impact the ability to earn a living, but the degree of this impact is uncertain; the ability to work among patients with RA has improved over the last three decades, and has been shown to vary depending upon a number of factors, including disease activity and physical function, work-environment, educational level, and potential for adapting work to limitations posed by the disease [<a href="#rid32">32-38</a>]. Work productivity may be adversely affected even when employment is maintained.</p><p>Early studies suggested that employment of patients with RA was approximately one-half that of unaffected individuals [<a href="#rid37">37,38</a>]. However, subsequent surveys report similar employment rates among patients with or without RA. As an example, after adjustment for level of education, sex, and age among individuals in the Netherlands, the rates of employment for patients with RA compared with that of the general population were not significantly different (61 versus 65 percent, respectively) [<a href="#rid32">32</a>]. A subsequent study from Sweden suggested that treatment with tumor necrosis factor (TNF) inhibitors was associated with a 35 percent increase in employment rate, suggesting that biologic therapy may have had additional benefit [<a href="#rid33">33</a>].</p><p>Important factors that influence capacity to maintain employment include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risk of work disability</strong> – The following features related to RA have been noted to increase the likelihood of being unable to work [<a href="#rid34">34-36</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pain</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired physical function</p><p class="bulletIndent2"><span class="glyph">•</span>Difficulty commuting to work</p><p class="bulletIndent2"><span class="glyph">•</span>Failure of antirheumatic drug therapy to produce significant improvement in disease activity, using measurements such as the ACR 20 percent response (ACR20) and Disease Activity Scores (eg, DAS28)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased risk of work disability</strong> – The presence of other factors is significantly associated with a decreased risk of being disabled, including [<a href="#rid34">34,36</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Being self-employed</p><p class="bulletIndent2"><span class="glyph">•</span>Having ergonomic improvements made at the work site</p><p class="bulletIndent2"><span class="glyph">•</span>Reporting a positive attitude about the importance of work</p><p class="bulletIndent2"><span class="glyph">•</span>Having at least an ACR20 response to antirheumatic therapy</p><p></p><p class="bulletIndent1">Employment status (ie, whether a patient is working or not) does not fully capture the economic impact of the disease as it relates to the workplace. The productivity of patients who continue to work may be adversely affected by disease-related absences and work restrictions [<a href="#rid39">39</a>].</p><p></p><p>A number of instruments assessing work-productivity, several of which are RA specific, have been evaluated in the context of arthritis [<a href="#rid40">40</a>]. While typically used in the research setting, the RA-specific instruments (the Rheumatoid Arthritis Specific Work Productivity Survey [WPS-RA] and the Work Instability Scale for Rheumatoid Arthritis [RA-WIS]) have the potential to be used in clinical practice. The WPS-RA has 9 questions and is easy to administer and score. Permission is required for its use. The RA-WIS has 23 questions and takes more time than the WPS-RA to administer and score. It is copyrighted and also requires permission to use.</p><p class="headingAnchor" id="H7"><span class="h1">IMPACT OF COMORBIDITIES</span></p><p class="headingAnchor" id="H2472318739"><span class="h2">Range of disorders and causes</span><span class="headingEndMark"> — </span>People with rheumatoid arthritis (RA) tend to have an increased prevalence of other serious comorbidities; the most common include infection, renal impairment, lymphoma, depression, gastroduodenal ulcer disease, asthma, chronic obstructive pulmonary disease (COPD), solid malignancies, and ischemic cardiovascular disease [<a href="#rid41">41,42</a>].</p><p>The bases for the prevalence of these comorbidities in RA include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The specific comorbidity and RA share risk factors (eg, smoking is a risk factor for both RA and asthma/COPD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RA causes the comorbidity (eg, chronically elevated inflammatory cytokines accelerate atherogenesis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pain and debility of RA contribute to the comorbidity (eg, depression).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RA pharmacotherapies are risk factors for the comorbidity (eg, nonsteroidal antiinflammatory drugs [NSAIDs] are risk factors for gastric ulcers and cardiovascular disease, and glucocorticoids are risk factors for infection).</p><p></p><p>RA patients often have multiple concomitant comorbidities. In a study of over 100,000 patients with RA, the odds of having two or three comorbid diseases were greater than two-fold higher for people with RA compared with non-RA controls [<a href="#rid43">43</a>], and RA patients accumulated more additional comorbidities over time than the non-RA group. Individuals' comorbidities and, particularly, multimorbidity contribute to physical dysfunction and the reduced quality of life associated with RA [<a href="#rid44">44</a>] and can even be fatal.</p><p>The impact of comorbidities on disease management is described separately. (See  <a class="medical medical_review" href="/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Comorbidities and disease management'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infections, particularly pulmonary, skin, and joint infections, occur with increased frequency in RA [<a href="#rid45">45</a>]. The reason is incompletely understood, but the following factors may contribute [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression by the disease itself or its treatment, including glucocorticoids and biologic disease-modifying antirheumatic drugs (DMARDs)</p><p class="bulletIndent1"><span class="glyph">●</span>The presence (often subclinical) of inflammatory lung disease</p><p class="bulletIndent1"><span class="glyph">●</span>An increase in cigarette smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Multiple factors associated with disability and immobility</p><p></p><p>Immunosuppression from use of glucocorticoids and immunosuppressive agents is probably the most important [<a href="#rid47">47</a>]. However, the highest glucocorticoid doses are used in the patients with most active disease, which also may contribute to the infection risk. Consistent with this hypothesis is the observation in a population-based study of 609 RA patients and an equal number of controls that RA remained an independent risk factor for infection after adjustment for glucocorticoid use, leukopenia, age, cigarette smoking, and diabetes [<a href="#rid45">45</a>]. Infections that required hospitalization were more common among patients with RA, compared with controls (adjusted hazard ratio 1.83, 95% CI 1.52-2.21). (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>In contrast with the increased risk of infection associated with the use of glucocorticoids and potent immunosuppressives, the use of nonbiologic (conventional synthetic) DMARDs (csDMARDs) does not appear to be associated with an increased risk of infection. This was illustrated in a retrospective study of 27,710 Canadian patients with RA, in which the risk of serious infection among patients not taking glucocorticoids was similar in both DMARD users and nonusers [<a href="#rid48">48</a>]. In contrast to csDMARDs, all available biologic DMARDs are associated with an increased risk of infections. In a 2019 meta-analysis , overall infection risk among over 11,000 RA patients treated with Janus kinase (JAK) inhibitors was not increased, compared with patients on conventional DMARDs [<a href="#rid49">49</a>]. One exception was a nearly threefold increase in herpes zoster infections.</p><p>Neutropenia and increased susceptibility to infection are consequences of both Felty syndrome and the large granular lymphocyte syndrome (see  <a class="medical medical_review" href="/d/html/7482.html" rel="external">"Clinical manifestations and diagnosis of Felty syndrome"</a>). Even in the absence of the full-blown syndrome, mild lymphopenia is very common in RA and may increase the susceptibility to infection. Lymphopenia commonly occurs with glucocorticoid treatment, and both csDMARDS and targeted synthetic DMARDs (tsDMARDs), but it is rarely of clinical significance.</p><p class="headingAnchor" id="H9"><span class="h2">Renal disease</span><span class="headingEndMark"> — </span>Renal disease directly related to RA is rare, and chronic inflammation and drug-related renal disease are very infrequent causes of renal compromise as well. Renal diseases associated with RA are described in more detail separately. (See  <a class="medical medical_review" href="/d/html/7511.html" rel="external">"Overview of the systemic and nonarticular manifestations of rheumatoid arthritis", section on 'Kidney disease'</a>.).</p><p>Secondary (AA) amyloidosis due to chronic inflammation is possible, although trends to more aggressive RA management have made observing this outcome rare. Membranous nephropathy due to gold and <a class="drug drug_general" data-topicid="9747" href="/d/drug information/9747.html" rel="external">penicillamine</a> use is no longer observed, since these drugs are no longer part of the treatment regimen for RA. Although NSAID use is still frequent in RA, NSAID prevalence and dose are lower than in previous eras. Thus, NSAID nephrotoxicity is now relatively uncommon in the RA population. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a> and  <a class="medical medical_review" href="/d/html/5602.html" rel="external">"Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"</a> and  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Lymphoproliferative disorders</span><span class="headingEndMark"> — </span>Lymphoproliferative disorders occur with increased frequency in patients with RA; incidence and mortality rates due to leukemia or lymphoma are approximately twofold higher than expected; the lymphoma incidence increases as active RA persists and correlates with the severity of disease activity. Additionally, drugs used to treat the disease, including alkylating agents, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), potentially biologic DMARDs, and tsDMARDs, may contribute to the risk, although not all patients with RA who develop malignancies have been treated with any of these agents. The etiology of neoplasia in such patients may include immune dysregulation and/or chronic immune activation. The evidence supporting these observations is described separately. (See  <a class="medical medical_review" href="/d/html/7512.html" rel="external">"Hematologic complications of rheumatoid arthritis", section on 'Hematologic malignancies'</a>.)</p><p>Up to one-third of patients with the large granular lymphocyte (LGL) leukemia have RA and may fulfill the clinical criteria for Felty syndrome. LGL leukemia in RA is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7489.html" rel="external">"Large granular lymphocyte leukemia in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Observational studies suggest that RA is associated with an increased risk of cardiovascular disease that appears to correlate with the activity and duration of the RA. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7492.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Implications for prevention and management"</a> and  <a class="medical medical_review" href="/d/html/7481.html" rel="external">"Coronary artery disease in rheumatoid arthritis: Pathogenesis, risk factors, clinical manifestations, and diagnostic implications"</a> and  <a class="medical medical_review" href="/d/html/7493.html" rel="external">"Heart failure in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">MORTALITY</span></p><p class="headingAnchor" id="H675702020"><span class="h2">Increased mortality rates</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) is a potentially fatal illness; levels of premature all-cause mortality relative to the general population appear to be decreasing, but cardiovascular risks remain elevated in most studies [<a href="#rid50">50-54</a>].</p><p>As examples, a nationwide Norwegian cohort study of 36,095 patients with RA demonstrated that RA is associated with an increase in all-cause mortality (hazard ratio 1.45, 95% CI 1.41-1.48), primarily due to cardiovascular disease, neoplasm, and respiratory illness [<a href="#rid55">55</a>]. Another study, involving 3501 patients with RA followed for up to 35 years, found that mortality was increased twofold, resulting in a decreased lifespan of 7 to 10 years (<a class="graphic graphic_figure graphicRef72445" href="/d/graphic/72445.html" rel="external">figure 1</a>) [<a href="#rid51">51</a>]. Other studies have shown that RA patients have a 50 percent increased risk of premature mortality, with life expectancy decreased by 3 to 10 years [<a href="#rid56">56</a>]. Mortality directly due to RA itself was low (9.8 percent of the deaths), although precise causes were not reported.</p><p>A portion of the marked increase in mortality in some reports may reflect referral bias, as many of these patients were being treated in large tertiary care centers. In a community-based study of 450 adult patients with RA, for example, the increased death rate was somewhat less than that observed in large medical centers [<a href="#rid57">57</a>]. The ratio of observed to expected deaths (standardized mortality ratio [SMR]) was 1.38 overall, with women bearing the highest risk (SMR of 1.55 and 1.07 for females and males, respectively). Additional data reported in 2003 based upon analysis of this almost exclusively White North American population confirmed a modest age- and sex-adjusted increase in mortality rates (SMR 1.27, 95% CI 1.13-1.41) with no significant change in the risk of premature death during the 40-year period of observation [<a href="#rid58">58</a>].</p><p>Improvements in therapy have not yet normalized survival for all populations with RA relative to the general population, although evidence of a narrowing of the mortality gap for patients with RA comes from a 2021 report from Denmark, which found similar 10-year all-cause mortality for patients with RA and the general population, although rates of cardiovascular disease remained higher among patients with RA [<a href="#rid59">59</a>]; and some studies continue to show a gap between mortality rates in patients with RA and the improving mortality rate in the general population [<a href="#rid56">56</a>]. Meta-analyses from 2008 and 2009 have also shown a 50 to 60 percent increased risk of mortality from cardiovascular disease [<a href="#rid60">60,61</a>]; and one of these studies showed no change in SMR over a 50-year period [<a href="#rid61">61</a>]. By contrast, in another study, in which patients with RA were followed from 1980 to 1997, lower rates of death due to acute myocardial infarction, which were similar to the general population, were noted in the patients diagnosed and treated in the 1990s [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H963317346"><span class="h2">Risk factors for premature mortality</span><span class="headingEndMark"> — </span>Independent predictors of mortality primarily include markers associated with increased clinical severity [<a href="#rid51">51,56,63-65</a>]. These include age, lower educational level, male sex (<a class="graphic graphic_figure graphicRef72445" href="/d/graphic/72445.html" rel="external">figure 1</a>), reduced physical function, rheumatoid factor and anti-citrullinated peptide antibodies, rheumatoid nodules, elevated erythrocyte sedimentation rate and C-reactive protein, elevated Disease Activity Score in 28 joints (DAS28 score), greater joint counts, use of NSAIDs and of glucocorticoids.</p><p>Other factors associated with an increased mortality rate include a lower than ideal body weight (body mass index &lt;20) [<a href="#rid66">66</a>], the presence of extraarticular disease, depression [<a href="#rid67">67</a>], circulating immune complexes [<a href="#rid52">52</a>], increased levels of soluble tumor necrosis factor receptors [<a href="#rid68">68</a>], and the presence of certain human leukocyte antigen (HLA) DRB1 alleles [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/7487.html" rel="external">"HLA and other susceptibility genes in rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H2624173629"><span class="h2">Causes of death</span><span class="headingEndMark"> — </span>The more common causes of death in patients with RA have been related to comorbid illnesses, particularly cardiovascular and cerebrovascular disease, infection, lymphomas, and gastrointestinal bleeding. Mechanisms by which premature mortality can occur in RA also include amyloidosis, transection of the cord due to cervical spine instability, and respiratory failure due to interstitial lung disease.</p><p>Patients with RA with a first cardiovascular event appear to have a higher mortality rate during the subsequent 30 days than those without RA (18 versus 11 percent) [<a href="#rid70">70</a>]. The reason for the difference in fatalities is uncertain. Possible explanations include a greater prevalence of severe epicardial coronary artery disease in patients with RA who present with new ischemic symptoms [<a href="#rid71">71</a>] and the presence of small vessel disease that is not amenable to angioplasty or bypass surgery [<a href="#rid72">72</a>].</p><p>Some studies have found a decrease or at least no increase in the expected number of deaths from cancer, probably reflecting the increase from other causes [<a href="#rid73">73</a>]. However, one large study of over 20,000 patients with RA reported an increased incidence of death resulting from lung cancer [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/5615.html" rel="external">"Malignancy and rheumatic disorders", section on 'Rheumatoid arthritis'</a>.)</p><p class="headingAnchor" id="H3726618044"><span class="h2">Impact of therapy</span><span class="headingEndMark"> — </span>Patients who respond to therapy, particularly a disease-modifying antirheumatic drug (DMARD), may have lower mortality, as shown in observational studies involving <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) and biologic DMARDs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methotrexate</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One long-term prospective study of 271 patients begun on MTX found that the group with more than 50 percent improvement had a less elevated rate of observed to expected deaths (standardized mortality ratio [SMR]) compared with patients who had no improvement or who had discontinued treatment (SMR 1.47 versus 4.11 and 5.56, respectively) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In an observational study of a cohort of 1240 patients with RA at an outpatient arthritis center in North America with a total of 191 deaths. MTX was prescribed for 588 patients [<a href="#rid76">76</a>]. The group that received MTX had poorer prognostic indicators. After adjustment for confounding by indication and other factors the hazard ratio for all-cause mortality among MTX-treated patients compared with nonusers was 0.4 (95% CI 0.2-0.8). The mortality risk from cardiovascular disease was lower than the trend for reduced noncardiovascular mortality (0.3 versus 0.6). The patients in this study were treated beginning in the 1980s and 1990s, prior to the general availability of biologic DMARDs. Use of conventional synthetic DMARDs other than MTX did not result in any survival advantage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biologic DMARDs</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a post-hoc analysis of pooled safety data from clinical trials of the tumor necrosis factor (TNF) inhibitor <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> for patients with RA, treated patients had a lower SMR compared with the general population [<a href="#rid77">77</a>], although this finding could be confounded by the general exclusion of sicker patients from clinical trials. Similar results were seen in analyses of patients in trials of adalimumab for other inflammatory disorders. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study based upon data from the German RABBIT registry (comprising 8908 patients with RA), a lower risk of mortality was observed among those treated with TNF inhibitors, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, and other biologic DMARDs compared with biologic-naïve patients prescribed <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (adjusted hazard ratios 0.64, 95% CI 0.50-0.81; 0.57, 95% CI 0.39-0.84; and 0.64, 95% CI 0.42-0.99; respectively) [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/512.html" rel="external">"Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/513.html" rel="external">"Patient education: Rheumatoid arthritis treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H361188233"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>The outcome of rheumatoid arthritis (RA) depends upon the degree of disease activity, joint damage, the physical functional status of the patient, psychological health, and the presence of comorbid illness. (See <a class="local">'Disease course and outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of functional capacity in RA is a result of the summation of loss of function in individual joints, which depends upon numerous factors. Since functional capacity is an important determinant of the natural history of RA and is a useful tool for assessing the effectiveness of therapeutic interventions, many instruments for patient evaluation have been developed. (See <a class="local">'Functional capacity'</a> above and <a class="local">'Assessment of functional status'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The long-term functional outlook is variable for patients who present early in the course of their illness and are treated. The combination of inflammation and joint damage leads to functional impairment. The impact of RA on the ability to earn a living is uncertain. (See <a class="local">'Long-term outcomes'</a> above and <a class="local">'Impact on employment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with RA have an increased prevalence of other serious illnesses. The predominant conditions contributing to the comorbidity and mortality of RA are (<a class="graphic graphic_table graphicRef82537" href="/d/graphic/82537.html" rel="external">table 1</a>) (see <a class="local">'Impact of comorbidities'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infections, particularly pulmonary, skin, and joint infections, which occur with increased frequency in RA (see <a class="local">'Infection'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Renal impairment, which is uncommon but may be due to RA itself or drug therapy (see <a class="local">'Renal disease'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphoproliferative disorders, including lymphoma, which occur with increased frequency in patients with RA (see <a class="local">'Lymphoproliferative disorders'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Cardiovascular disease, which appears to correlate with the activity and duration of the RA (see <a class="local">'Cardiovascular disease'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>RA patients have an increased risk of premature mortality, and their life expectancy is decreased, although most of the mortality is not due directly to RA itself. (See <a class="local">'Mortality'</a> above.)</p><p></p><p class="headingAnchor" id="H3368929633"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Ravinder N Maini, BA, MB BChir, FRCP, FMedSci, FRS and PJW Venables, MA, MB BChir, MD, FRCP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.</a></li><li><a class="nounderline abstract_t">Markusse IM, Akdemir G, Dirven L, et al. Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Ann Intern Med 2016; 164:523.</a></li><li><a class="nounderline abstract_t">Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54:2784.</a></li><li><a class="nounderline abstract_t">Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48:59.</a></li><li><a class="nounderline abstract_t">Giles JT, Ling SM, Ferrucci L, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 2008; 59:807.</a></li><li><a class="nounderline abstract_t">Giles JT, Bartlett SJ, Andersen RE, et al. Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthritis Rheum 2008; 59:1407.</a></li><li><a class="nounderline abstract_t">Kramer HR, Fontaine KR, Bathon JM, Giles JT. Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes. Arthritis Rheum 2012; 64:2438.</a></li><li><a class="nounderline abstract_t">Baker JF, Giles JT, Weber D, et al. Assessment of muscle mass relative to fat mass and associations with physical functioning in rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:981.</a></li><li><a class="nounderline abstract_t">Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One 2018; 13:e0195123.</a></li><li><a class="nounderline abstract_t">Lusa AL, Amigues I, Kramer HR, et al. Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics. Arthritis Care Res (Hoboken) 2015; 67:21.</a></li><li><a class="nounderline abstract_t">Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42:1854.</a></li><li><a class="nounderline abstract_t">Escalante A, del Rincón I. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? Arthritis Rheum 1999; 42:1712.</a></li><li><a class="nounderline abstract_t">Barber CEH, Zell J, Yazdany J, et al. 2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2019; 71:1531.</a></li><li><a class="nounderline abstract_t">Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988; 15:1480.</a></li><li><a class="nounderline abstract_t">Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30:167.</a></li><li><a class="nounderline abstract_t">Fries JF, Ramey DR. "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol 1997; 24:1697.</a></li><li><a class="nounderline abstract_t">Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res 1992; 5:119.</a></li><li><a class="nounderline abstract_t">Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137.</a></li><li><a class="nounderline abstract_t">Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982; 9:789.</a></li><li class="breakAll">Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 - Status and Review. In: Pharmacoeconomics and Quality of Life in Clinical Trials, Second edition, B. Spilker (Ed), Raven Press, New York 1996. p.227-237.</li><li><a class="nounderline abstract_t">Yazdany J, Bansback N, Clowse M, et al. Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. Arthritis Care Res (Hoboken) 2016; 68:1866.</a></li><li><a class="nounderline abstract_t">Hawley DJ, Wolfe F. Anxiety and depression in patients with rheumatoid arthritis: a prospective study of 400 patients. J Rheumatol 1988; 15:932.</a></li><li><a class="nounderline abstract_t">Meenan RF, Mason JH, Anderson JJ, et al. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 1992; 35:1.</a></li><li><a class="nounderline abstract_t">Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002; 61:1055.</a></li><li><a class="nounderline abstract_t">Ten Klooster PM, Oude Voshaar MAH, Fakhouri W, et al. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy. Clin Rheumatol 2019; 38:2727.</a></li><li><a class="nounderline abstract_t">Heinimann K, von Kempis J, Sauter R, et al. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med 2018; 7.</a></li><li><a class="nounderline abstract_t">Gwinnutt JM, Norton S, Hyrich KL, et al. Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology (Oxford) 2022; 61:4687.</a></li><li><a class="nounderline abstract_t">Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. PLoS Med 2020; 17:e1003296.</a></li><li><a class="nounderline abstract_t">Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354:1932.</a></li><li><a class="nounderline abstract_t">Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594.</a></li><li><a class="nounderline abstract_t">Breedveld FC, Han C, Bala M, et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64:52.</a></li><li><a class="nounderline abstract_t">Chorus AM, Miedema HS, Wevers CJ, van Der Linden S. Labour force participation among patients with rheumatoid arthritis. Ann Rheum Dis 2000; 59:549.</a></li><li><a class="nounderline abstract_t">Olofsson T, Petersson IF, Eriksson JK, et al. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work? Ann Rheum Dis 2017; 76:1245.</a></li><li><a class="nounderline abstract_t">Lacaille D, Sheps S, Spinelli JJ, et al. Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Rheum 2004; 51:843.</a></li><li><a class="nounderline abstract_t">Puolakka K, Kautiainen H, Möttönen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 2005; 64:130.</a></li><li><a class="nounderline abstract_t">Puolakka K, Kautiainen H, Möttönen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52:36.</a></li><li><a class="nounderline abstract_t">Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30:507.</a></li><li><a class="nounderline abstract_t">Doeglas D, Suurmeijer T, Krol B, et al. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995; 54:455.</a></li><li><a class="nounderline abstract_t">Lo J, Chan L, Flynn S. A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update. Arch Phys Med Rehabil 2021; 102:115.</a></li><li><a class="nounderline abstract_t">Tang K, Beaton DE, Boonen A, et al. Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11:S337.</a></li><li><a class="nounderline abstract_t">Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014; 73:62.</a></li><li><a class="nounderline abstract_t">Berkanovic E, Hurwicz ML. Rheumatoid arthritis and comorbidity. J Rheumatol 1990; 17:888.</a></li><li><a class="nounderline abstract_t">England BR, Roul P, Yang Y, et al. Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. Ann Rheum Dis 2021; 80:286.</a></li><li><a class="nounderline abstract_t">Luque Ramos A, Redeker I, Hoffmann F, et al. Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey. J Rheumatol 2019; 46:564.</a></li><li><a class="nounderline abstract_t">Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287.</a></li><li><a class="nounderline abstract_t">Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46:2294.</a></li><li><a class="nounderline abstract_t">Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35:387.</a></li><li><a class="nounderline abstract_t">Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59:1074.</a></li><li><a class="nounderline abstract_t">Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 2019; 58:1755.</a></li><li><a class="nounderline abstract_t">Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients. Am J Med 2003; 115:371.</a></li><li><a class="nounderline abstract_t">Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481.</a></li><li><a class="nounderline abstract_t">Erhardt CC, Mumford PA, Venables PJ, Maini RN. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48:7.</a></li><li><a class="nounderline abstract_t">Kazis LE, Anderson JJ, Meenan RF. Health status as a predictor of mortality in rheumatoid arthritis: a five-year study. J Rheumatol 1990; 17:609.</a></li><li><a class="nounderline abstract_t">Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13:841.</a></li><li><a class="nounderline abstract_t">Kerola AM, Kazemi A, Rollefstad S, et al. All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study. Rheumatology (Oxford) 2022; 61:4656.</a></li><li><a class="nounderline abstract_t">Myasoedova E, Davis JM 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010; 12:379.</a></li><li><a class="nounderline abstract_t">Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26:2529.</a></li><li><a class="nounderline abstract_t">Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54.</a></li><li><a class="nounderline abstract_t">Løgstrup BB, Ellingsen T, Pedersen AB, et al. Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. Rheumatology (Oxford) 2021; 60:1400.</a></li><li><a class="nounderline abstract_t">Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59:1690.</a></li><li><a class="nounderline abstract_t">Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009; 48:1309.</a></li><li><a class="nounderline abstract_t">Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004; 110:1774.</a></li><li><a class="nounderline abstract_t">Myllykangas-Luosujärvi R, Aho K, Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995; 22:2214.</a></li><li><a class="nounderline abstract_t">Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48:1530.</a></li><li><a class="nounderline abstract_t">Gonzalez A, Icen M, Kremers HM, et al. Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol 2008; 35:1009.</a></li><li><a class="nounderline abstract_t">Escalante A, Haas RW, del Rincón I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624.</a></li><li><a class="nounderline abstract_t">Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005; 32:1013.</a></li><li><a class="nounderline abstract_t">Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:3940.</a></li><li><a class="nounderline abstract_t">Mattey DL, Thomson W, Ollier WE, et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56:1408.</a></li><li><a class="nounderline abstract_t">Van Doornum S, Brand C, King B, Sundararajan V. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:2061.</a></li><li><a class="nounderline abstract_t">Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005; 7:R984.</a></li><li><a class="nounderline abstract_t">Raza K, Banks M, Kitas GD. Reversing myocardial microvascular disease in a patient with rheumatoid arthritis. J Rheumatol 2005; 32:754.</a></li><li><a class="nounderline abstract_t">van den Borne BE, Landewé RB, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41:1930.</a></li><li><a class="nounderline abstract_t">Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A:1753.</a></li><li><a class="nounderline abstract_t">Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43:14.</a></li><li><a class="nounderline abstract_t">Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.</a></li><li><a class="nounderline abstract_t">Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68:1863.</a></li><li><a class="nounderline abstract_t">Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 2015; 74:415.</a></li></ol></div><div id="topicVersionRevision">Topic 7505 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567728" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089068" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16947781" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528104" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Functional disability in rheumatoid arthritis patients compared with a community population in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512711" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821641" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22391952" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Muscle density in rheumatoid arthritis: associations with disease features and functional outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28340012" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Assessment of muscle mass relative to fat mass and associations with physical functioning in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771924" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Obesity and response to anti-tumor necrosis factor-αagents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155859" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Indicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513799" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10446872" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : How much disability in rheumatoid arthritis is explained by rheumatoid arthritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31709771" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3204597" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12508408" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292790" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457486" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The health assessment questionnaire 1992: status and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7362664" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Measurement of patient outcome in arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7175852" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7175852" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27696755" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3418643" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Anxiety and depression in patients with rheumatoid arthritis: a prospective study of 400 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731806" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429534" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31161488" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29533997" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35274696" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32960885" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10622295" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096166" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286005" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10873966" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Labour force participation among patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073801" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15478162" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Identification of modifiable work-related factors that influence the risk of work disability in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608311" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641055" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3593434" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The work dynamics of the person with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632086" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Work disability in early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339483" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A Systematic Review of the Incidence, Prevalence, Costs, and Activity and Work Limitations of Amputation, Osteoarthritis, Rheumatoid Arthritis, Back Pain, Multiple Sclerosis, Spinal Cord Injury, Stroke, and Traumatic Brain Injury in the United States: A 2019 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22588755" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQ), and Work Productivity and Activity Impairment Questionnaire (WPAI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24095940" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213754" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rheumatoid arthritis and comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33032999" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30647170" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Comorbidities in Patients with Rheumatoid Arthritis and Their Association with Patient-reported Outcomes: Results of Claims Data Linked to Questionnaire Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355475" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355476" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Predictors of infection in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260176" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The risk of hospitalized infection in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668604" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982883" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14553872" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998:a longitudinal study of 3035 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8147925" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The mortality of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2923507" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2359069" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Health status as a predictor of mortality in rheumatoid arthritis: a five-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3820193" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Taking mortality in rheumatoid arthritis seriously--predictive markers, socioeconomic status and comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35377442" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20645137" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606358" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Mortality in rheumatoid arthritis: have we made an impact in 4 decades?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528103" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32984893" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035419" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696061" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15381644" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8835551" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794820" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Predicting mortality in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412312" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Mortality trends in rheumatoid arthritis: the role of rheumatoid factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043681" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15940760" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18050238" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469097" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16802340" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16207339" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15801038" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Reversing myocardial microvascular disease in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9811046" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8983286" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Rheumatoid arthritis and cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643695" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955534" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147611" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24291654" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFαinhibitors and rituximab.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
